Rockwell Medical Appoints VP, Strategic Accounts
WIXOM, Mich., Oct. 1, 2018
WIXOM, Mich., Oct. 1, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company" or "Rockwell Medical") today announced that Anne Boardman has been appointed Vice President, Strategic Accounts, effective today, October 1, 2018. In this newly-established roll, Ms. Boardman will report to Stuart Paul, President & Chief Executive Officer of the Company.
Ms. Boardman has substantial experience in renal, biotech and medical sales, sales management and large corporate account management throughout her 30-year career. In recent years, Ms. Boardman served as VP, Strategic Accounts at Gambro Healthcare, and led the U.S. team responsible for contracting and deploying the full portfolio of Gambro products and therapies to support Dialysis clinics, in addition to managing numerous strategic customer relationships. She also served as Director of Integrated Delivery Networks, US Hospital Products at Baxter HealthCare, where she meaningfully grew product sales in critical accounts and built and maintained numerous value-based relationships. Earlier in her career, Ms. Boardman was employed by Watson Nephrology and Genzyme Therapeutics.
Mr. Paul said, "We are delighted to welcome a well-rounded commercial leader such as Anne to the Company. I had the pleasure of working alongside Anne during my time at Gambro AB and saw first-hand her ability to build, improve and manage critical business relationships. This is in addition to her proven track record in contracting and executing deployment strategies within various corporate accounts. Anne is a highly accomplished professional with significant experience in the renal space and has a strong understanding of the reimbursement landscape, all of which will be valuable to Rockwell Medical as we move forward."
Ms. Boardman said, "I am thrilled to be joining Rockwell Medical at this important time in the Company's history as we move forward with commercialization and plan to draw on my strong clinical and business background, particularly within the renal space, in addition to my sales and account management experience. I am excited to work alongside Stuart and look forward to hitting the ground running and getting to know the rest of the Rockwell Medical team."
About Rockwell Medical, Inc.
Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD). Rockwell Medical's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical's anemia drug Triferic is the only FDA-approved product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell's FDA approved generic drug Calcitriol (active vitamin D) is for treating secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates (used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream) to dialysis providers and distributors in the U.S. and abroad. Please visit www.rockwellmed.com for more information.
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to bring to market Triferic and Calcitriol. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "plan," "potential," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: statements about our liquidity and capital resources; our ability to maintain compliance with SEC and NASDAQ rules and requirements; plans relating to the commercialization of Triferic and Calcitriol; the timing and ability of the Company to obtain add-on reimbursement for Triferic; the Company's ability to obtain FDA and EMA approval of the intraveneous formulation of Triferic; and whether the Company can successfully execute on its new business strategy. Rockwell expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Dan Katcher / Kelly Sullivan / Arielle Rothstein
Joele Frank, Wilkinson Brimmer Katcher
SOURCE Rockwell Medical, Inc.